Law360, New York (June 03, 2010, 5:37 PM ET) -- Purdue Pharma Products LP has lost its appeal of a district court ruling that the company's patents for tramadol are invalid, clearing the way for Par Pharmaceuticals Inc. to market a generic version of the painkiller.
The U.S. Court of Appeals for the Federal Circuit on Thursday upheld a district court's ruling that Purdue's U.S. Patent Numbers 6,254,887 and 7,074,430 were obvious in light of earlier patents for controlled-release formulations of tramadol including U.S. Patent Number 5,580,578, known as the Oshlack patent.
Purdue had argued that...
Fed. Circ. Deems Purdue's Tramadol Patents Invalid
To view the full article, take a free trial now.
